Abstract：
:The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the vasotoxicity of a disturbed homocysteine metabolism. Unfortunately, most in vitro studies use physiologically irrelevant concentrations or forms, or both, of homocysteine. The role of the different oxidized and reduced forms of homocysteine in its metabolism has gained little attention. In the cell, homocysteine is mainly present in its reduced form. In this article export of homocysteine out of the cell is reported to be regulated by a "reduced-homocysteine carrier." In vitro endothelial cells export homocysteine at a constant rate in a folate dose-dependent matter. Even at high-normal folate levels, endothelial cells export homocysteine. As soon as homocysteine is exported out of the cell, it will be oxidized to a disulfide with any compound containing a thiol function or undergo a disulfide exchange reaction, both resulting in formation of disulfides of homocysteine. Consequently, in plasma, about 99% of homocysteine is bound to disulfides. Before homocysteine can be metabolized, it needs to be taken up by the cell via carriers, channels, or receptors recognizing the different homocysteine disulfides. In the cell, the homocysteine disulfides are reduced, liberating homocysteine in its reduced form. Next, homocysteine can be metabolized after binding to the homocysteine-converting enzymes. In particular, the liver and kidney supposedly take up and metabolize significant amounts of homocysteine.
journal_name
Semin Thromb Hemostjournal_title
Seminars in thrombosis and hemostasisauthors
Blom HJdoi
10.1055/s-2000-8467subject
Has Abstractpub_date
2000-01-01 00:00:00pages
227-32issue
3eissn
0094-6176issn
1098-9064journal_volume
26pub_type
杂志文章,评审abstract：:Thrombosis is characterized by the formation of in vivo blood clots that are localized within arterial or venous blood vessels. These thrombi form beyond the need for physiologically healthy hemostatic responses and can lead to significant medical issues for affected individuals. Unfortunately, the existing standard-o...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0039-1697946
更新日期：2020-07-01 00:00:00
abstract：:In severe infection and sepsis, activation of coagulation frequently occurs, which contributes to the development of multiple organ dysfunction. Factor V Leiden is a relatively common mutation resulting in a mild prohemostatic state and consequently with an increased tendency to develop thrombosis. Hypothetically, pat...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0031-1297374
更新日期：2011-11-01 00:00:00
abstract：:This report describes the first two Japanese cases of AIDS developed in patients with hemophilia. One was a 48-year-old man with hemophilia B and the other was a 62-year-old patient with hemophilia A. They had nonspecific prodromal syndromes of AIDS initially, and later developed fatal opportunistic infections with Ca...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-2007-1004393
更新日期：1985-10-01 00:00:00
abstract：:There is a persuasive body of evidence suggesting that tissue factor (TF) is a major determinant of tumor progression. In addition to its "traditional" function as the initiator of hemostasis, TF may support tumor progression through signaling mechanisms involving either direct signal transduction through the TF cytop...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2008-1079255
更新日期：2008-03-01 00:00:00
abstract：:Clinical and laboratory data of children with von Willebrand disease (VWD) types have been derived from retrospective studies and small case series. This article reports on the clinical and laboratory data of a large pediatric cohort in one single Argentinian center. The biological and clinical responses to desmopress...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0031-1281043
更新日期：2011-07-01 00:00:00
abstract：:Available data suggest that elevated triglyceride levels in plasma, associated with increased VLDL or chylomicron remnants, are associated with premature coronary artery atherosclerosis. Whether this is a direct effect or as a result of the association of hypertriglyceridemia with decreased HDL as well as decreased LD...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2007-1002768
更新日期：1988-04-01 00:00:00
abstract：:Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those for congenital von Willebrand disease (VWD). Unlike VWD, AVWS usually occurs in individuals with no personal or family history of bleeding. The prevalence of AVWS in the general population is unknown because d...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0030-1270069
更新日期：2011-02-01 00:00:00
abstract：BACKGROUND:The normalized dilute Russell viper venom time (DRVVT) ratio provides a robust assay methodology for lupus anticoagulant (LA) detection. OBJECTIVES:We evaluated six normalized DRVVT LA screen and confirm systems for inter-method consistency. Reagents were purchased from Diagnostica Stago, Inc. (Parsippany, ...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0033-1334865
更新日期：2013-04-01 00:00:00
abstract：:Oral anticoagulants (OAs) are the drugs of choice for the prevention of recurrence and death in patients with venous thromboembolism (VTE). Oral anticoagulant treatment (OAT) aims to retard blood coagulation to obtain maximum protection against thromboembolic events with the lowest risk of bleeding. The intensity of O...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2006-955460
更新日期：2006-11-01 00:00:00
abstract：:Numerous studies have shown that early radiation injury is characterized by vascular damage and that the initial site of damage appears to be the EC lining of the vessel wall. Chronic irreversible tissue reactions to radiation include thrombotic occlusion of capillaries, enhanced atherosclerosis in larger vessels, inf...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-2007-1002708
更新日期：1989-04-01 00:00:00
abstract：:Immune thrombocytopenic purpura (ITP) is a bleeding disorder and is traditionally divided in acute and chronic forms based on the duration of the disease. Chronic ITP is characterized by a persistence of thrombocytopenia for more than 6 months. Ten to 20% of children with ITP and almost all adults will develop the chr...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2007-996054
更新日期：1998-01-01 00:00:00
abstract：:Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2001-18871
更新日期：2001-12-01 00:00:00
abstract：:von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0036-1592164
更新日期：2017-02-01 00:00:00
abstract：:Severe trauma is the leading cause of death globally. Though improved resuscitation, particularly early initiation, has reduced the 24-hour mortality rate, the overall morbidity and 30-day mortality remain high mostly due to massive hemorrhage and head injury in the early stages and sepsis and multiorgan failure later...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0039-3402428
更新日期：2020-03-01 00:00:00
abstract：:Although the current therapeutic armamentarium of venous thrombosis encompasses the use of vitamin K antagonists, heparins, and direct oral anticoagulants, these drugs have several important drawbacks. Antisense oligonucleotides are relatively short single-stranded nucleic acid sequences, which hybridize with a target...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0035-1546466
更新日期：2015-03-01 00:00:00
abstract：:Current concepts of etiology and pathophysiology resulting in disseminated intravascular coagulation (DIC) form the basis of treatment of this hemostatic disorder. Due to the heterogeneous triggering diseases and different kinds of DIC, clinical symptoms such as predominant bleeding, thromboembolic complications or or...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2007-995823
更新日期：1998-01-01 00:00:00
abstract：:A prospective management decision analysis for the exclusion and diagnosis of pulmonary embolism (PE) based on pre-test clinical probability (PCP) estimation for PE, a rapid ELISA D-dimer test, perfusion lungscan (P-scan), CUS, spiral CT, and pulmonary angiography is proposed. The modified PCP model for PE of Wells et...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2007-996031
更新日期：1998-01-01 00:00:00
abstract：:The hemostatic balance is a complex system where the delicate equilibrium is regulated by several factors including hormones. A variety of endocrine disorders have been reported to be associated with coagulation abnormalities, ranging from mild laboratory changes to clinically relevant thrombotic or bleeding manifesta...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0030-1270065
更新日期：2011-02-01 00:00:00
abstract：:Impaired placental development is a well-known pathogenesis in preeclampsia. The present study was undertaken to elucidate the involvement of fibrinolytic factors in amniotic fluid in midtrimester with development of severe early-onset preeclampsia. Amniotic fluid was obtained by amniocentesis at 15 to 18 weeks of ges...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-2007-994948
更新日期：1999-01-01 00:00:00
abstract：:Platelet-lowering therapy in myeloproliferative disorders includes cytostatic drugs, mainly hydroxyurea, interferon alpha, and anagrelide. Anagrelide is the latest addition to the therapeutic arsenal, and the basis for its use is reviewed. The platelet-lowering efficacy is 70 to 80% in essential thrombocythemia, and t...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2006-939437
更新日期：2006-04-01 00:00:00
abstract：:Endothelial phenotypic heterogeneity plays an important role in the susceptibility of the cardiovascular system to disease. Arteries and heart valves are susceptible to chronic inflammatory disease in regions of blood flow disturbance that implicates hemodynamic forces and transport characteristics as prominent influe...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0030-1253449
更新日期：2010-04-01 00:00:00
abstract：:Anticoagulant therapy reduces deaths and disability in patients with or at risk of both arterial and venous thromboembolism. Highly effective antithrombotic therapies now exist that reduce the risk of both arterial thrombosis and venous thrombosis. Anticoagulant strategies include platelet inhibition, using a variety ...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0032-1326788
更新日期：2012-10-01 00:00:00
abstract：:This study aimed to determine the impact of major hemorrhage (MH) protocol (MHP) activation on blood administration and patient outcome at a UK major cardiothoracic center. MH was defined in patients (> 16 years) as those who received > 5 units of red blood cells (RBCs) in < 4 hours, or > 10 units in 24 hours. Data we...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0040-1718869
更新日期：2021-02-01 00:00:00
abstract：:Point-of-care (POC) testing in hemostasis has experienced a significant increase in the spectrum of available tests and the number of tests performed. Short turn-around time and observation of rapid changes in test results are facilitated. The quality control process in POC testing must encompass a preanalytic (collec...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-0035-1544184
更新日期：2015-02-01 00:00:00
abstract：:Congenital factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder with potentially life-threatening consequences. FXIII is composed of two subunits (A and B), and a deficiency or dysfunction of either can result in FXIII deficiency. Traditionally, FXIII deficiency has been managed by infusing ...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0036-1585076
更新日期：2017-02-01 00:00:00
abstract：:Thrombotic events are uncommon disorders in childhood but increasingly recognized due to the progress made in the understanding of the hemostasis system and the importance of thromboembolic disorders in children. Multiple clinical underlying conditions and prothrombotic disorders contribute to the development of throm...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2006-951457
更新日期：2006-10-01 00:00:00
abstract：: ...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 社论,历史文章
doi：10.1055/s-0038-1677460
更新日期：2019-02-01 00:00:00
abstract：:Rivaroxaban is approved in Europe and the United States for thromboprophylaxis following total joint arthroplasty. As the rate of obesity increases, confirming safety and efficacy in this patient population is paramount. This retrospective chart review assessed the efficacy and safety of rivaroxaban between two body m...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0038-1676319
更新日期：2019-03-01 00:00:00
abstract：:Thrombocytosis is frequently (10 to 57%) observed in cancer patients. Although the mechanisms underlying thrombocytosis are not yet fully elucidated, tumor-derived factors with thrombopoietin-like activity, growth factors, platelet-derived microparticles, and factors released from bone marrow endothelial cells as well...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章,评审
doi：10.1055/s-2007-991540
更新日期：2007-10-01 00:00:00
abstract：:The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...
journal_title：Seminars in thrombosis and hemostasis
pub_type： 杂志文章
doi：10.1055/s-0032-1313605
更新日期：1995-01-01 00:00:00
